David Raymond Ferry
Impact in
- Gastroenterology top 0.5%
- Gastrointestinal Tumor Research and Treatment
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 27
- Colorectal Cancer Treatments and Studies 14
-
- Gastric Cancer Management and Outcomes 12
- Lung Cancer Treatments and Mutations 8
- Co-authors
- Hartmut H. Glossmann (18 shared papers)Eric Van Cutsem (10 shared papers)David Cunningham (5 shared papers)Jaffer A. Ajani (4 shared papers)Kei Muro (5 shared papers)Atsushi Ohtsu (5 shared papers)A. Göll (7 shared papers)Hansjochen Wilke (3 shared papers)
- Journals
- Naunyn-Schmiedeberg s Archives of Pharmacology (9 papers)The Lancet Oncology (8 papers)Journal of Clinical Oncology (8 papers)Annals of Oncology (4 papers)European Journal of Cancer (4 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
David Raymond Ferry
97 papers receiving 12.5k citations
David Raymond Ferry's Hit Papers
Peers
Comparison fields: 5 of 137
- Gastroenterology 1.0k
- Oncology 4.8k
- Pulmonary and Respiratory Medicine 4.6k
- Hepatology 558
- Cardiology and Cardiovascular Medicine 1.3k
Countries citing papers authored by David Raymond Ferry
This map shows the geographic impact of David Raymond Ferry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Raymond Ferry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Raymond Ferry more than expected).
Fields of papers citing papers by David Raymond Ferry
This network shows the impact of papers produced by David Raymond Ferry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Raymond Ferry. The network helps show where David Raymond Ferry may publish in the future.
Co-authors
The 25 scholars most cited alongside David Raymond Ferry, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 101 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial Hit paper breakdown → | 2014 | 1964 |
| 2 | Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial Hit paper breakdown → | 2013 | 1781 |
| 3 | Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen Hit paper breakdown → | 2012 | 1128 |
| 4 | Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial Hit paper breakdown → | 2013 | 612 |
| 5 | Outcomes in Patients with Acute Non–Q-Wave Myocardial Infarction Randomly Assigned to an Invasive as Compared with a Conservative Management Strategy Hit paper breakdown → | 1998 | 587 |
| 6 | 2007 | 466 | |
| 7 | Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study Hit paper breakdown → | 2013 | 408 |
| 8 | 1982 | 284 | |
| 9 | 2014 | 271 | |
| 10 | 1999 | 269 | |
| 11 | 2002 | 255 | |
| 12 | 2011 | 254 | |
| 13 | 2019 | 241 | |
| 14 | 2019 | 234 | |
| 15 | 2014 | 205 | |
| 16 | 2013 | 182 | |
| 17 | Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial Hit paper breakdown → | 2022 | 178 |
| 18 | 1985 | 174 | |
| 19 | 2015 | 148 | |
| 20 | 2006 | 147 |
About David Raymond Ferry
David Raymond Ferry is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cellular and Molecular Neuroscience, Cardiology and Cardiovascular Medicine and Molecular Biology, having authored 101 papers that have together received 13.1k indexed citations. Recurring topics across this work include Ion channel regulation and function (17 papers), Colorectal Cancer Treatments and Studies (14 papers), Gastric Cancer Management and Outcomes (12 papers), Neuroscience and Neuropharmacology Research (11 papers), Lung Cancer Treatments and Mutations (8 papers), Esophageal Cancer Research and Treatment (6 papers), Receptor Mechanisms and Signaling (5 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). The work is most often cited by research in Gastroenterology (1.0k citations), Oncology (4.8k citations), Pulmonary and Respiratory Medicine (4.6k citations), Hepatology (558 citations) and Cardiology and Cardiovascular Medicine (1.3k citations). David Raymond Ferry has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Hartmut H. Glossmann, Eric Van Cutsem, David Cunningham, Jaffer A. Ajani, Kei Muro, Atsushi Ohtsu, A. Göll, Hansjochen Wilke, Gyorgy Bodoky and Michael Emig. Their work appears in journals such as Naunyn-Schmiedeberg s Archives of Pharmacology, The Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.